Worth reading
44Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
24.4
Year-on-year change in operating profit (%)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPNet Sales68,463Millions of yenYear on year +5.1%Progress 50.0%
Operating profit9,007Millions of yenYear on year +24.4%Progress 56.3%
Ordinary income10,855Millions of yenYear on year +22.8%Progress 53.0%
Net income attributable to owners of the parent6,188Millions of yenYear on year +9.3%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥58.09
Financial position at period-end
Total assets271,261Millions of yen
of which net assets 224,323 Millions of yenEquity ratio 75.2%vs. prior year-end +1.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenuePharmaceuticals business 32,167 Millions of yen (YoY +10.0%), Equipment business 9,211 Millions of yen (YoY -13.1%), Processing Business 25,652 Millions of yen (YoY +7.4%), Other 1,432 Millions of yen (YoY +1.4%)
Segment profitPharmaceuticals business 5,521 Millions of yen (YoY +12.6%), Equipment business 1,000 Millions of yen (YoY +168.3%), Processing Business 3,294 Millions of yen (YoY +25.2%), Other -21 Millions of yen (YoY +39.6%)
Regional sales43,670 Millions of yen (YoY +7.3%), 22,588 Millions of yen (YoY +5.2%), 6,382 Millions of yen (YoY +6.8%)
Outlook and shareholder returns
Full-year earnings forecast
Net Sales137,000 Millions of yen (YoY -1.5%)
Operating profit16,000 Millions of yen (YoY +1.9%)
Ordinary income20,500 Millions of yen (YoY +4.2%)
Profit attributable to owners of the parent14,500 Millions of yen (YoY +12.1%)
Revision to Earnings ForecastNet Sales 134,000 Millions of yen → 137,000 Millions of yen（+2.2%） / Operating profit 15,000 Millions of yen → 16,000 Millions of yen（+6.7%） / Ordinary income 19,000 Millions of yen → 20,500 Millions of yen（+7.9%） / Profit attributable to owners of the parent 14,000 Millions of yen → 14,500 Millions of yen（+3.6%）
Annual Dividend Forecast50 Yen → 50 Yen
Factors Behind Changes in Business Performance
Increased orders received in the chemicals and processing businesses and cost improvements in the equipment business. The disclosure also mentions higher costs due to increases in raw material prices, labor costs and other expenses, as well as the recognition of provisions for environmental measures and other items.
Disclosure regarding the going concern assumption
None
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name Not applicable
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets 7 Millions of yen, Gain on changes in equity 3 Millions of yen / Extraordinary loss Loss on disposal and sale of non-current assets 201 Millions of yen, Provision for environmental measures 1,078 Millions of yen, Loss on sale of investment securities 0 Millions of yen, Other 10 Millions of yen
Depreciation and amortization3,606 Millions of yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNo (no target participants specified)
Issued Shares at Period-End132,604,524
Treasury Shares at Period-End27,756,567
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | 68,463 Millions of yen (YoY +5.1%) |
| Operating profit | 9,007 Millions of yen (YoY +24.4%) |
| Ordinary income | 10,855 Millions of yen (YoY +22.8%) |
| Profit attributable to owners of the parent | 6,188 Millions of yen (YoY +9.3%) |
| Net income per share | ¥58.09 |
| Equity ratio | End of the current fiscal period 75.2 / End of previous period 73.9 |
| Total assets | 271,261 Millions of yen |
| Net assets | 224,323 Millions of yen |
| Full-year earnings forecast | Net Sales 137,000 Millions of yen (YoY -1.5%) / Operating profit 16,000 Millions of yen (YoY +1.9%) / Ordinary income 20,500 Millions of yen (YoY +4.2%) / Profit attributable to owners of the parent 14,500 Millions of yen (YoY +12.1%) |
| Revision to Earnings Forecast | Net Sales 134,000 Millions of yen → 137,000 Millions of yen（+2.2%） / Operating profit 15,000 Millions of yen → 16,000 Millions of yen（+6.7%） / Ordinary income 19,000 Millions of yen → 20,500 Millions of yen（+7.9%） / Profit attributable to owners of the parent 14,000 Millions of yen → 14,500 Millions of yen（+3.6%） |
| Annual Dividend Forecast | 50 Yen → 50 Yen |
| Segment revenue | Pharmaceuticals business 32,167 Millions of yen (YoY +10.0%), Equipment business 9,211 Millions of yen (YoY -13.1%), Processing Business 25,652 Millions of yen (YoY +7.4%), Other 1,432 Millions of yen (YoY +1.4%) |
| Segment profit | Pharmaceuticals business 5,521 Millions of yen (YoY +12.6%), Equipment business 1,000 Millions of yen (YoY +168.3%), Processing Business 3,294 Millions of yen (YoY +25.2%), Other -21 Millions of yen (YoY +39.6%) |
| Regional sales | 43,670 Millions of yen (YoY +7.3%), 22,588 Millions of yen (YoY +5.2%), 6,382 Millions of yen (YoY +6.8%) |
| Depreciation and amortization | 3,606 Millions of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 7 Millions of yen, Gain on changes in equity 3 Millions of yen / Extraordinary loss Loss on disposal and sale of non-current assets 201 Millions of yen, Provision for environmental measures 1,078 Millions of yen, Loss on sale of investment securities 0 Millions of yen, Other 10 Millions of yen |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No (no target participants specified) |
| Issued Shares at Period-End | 132,604,524 |
| Treasury Shares at Period-End | 27,756,567 |
| Factors Behind Changes in Business Performance | Increased orders received in the chemicals and processing businesses and cost improvements in the equipment business. The disclosure also mentions higher costs due to increases in raw material prices, labor costs and other expenses, as well as the recognition of provisions for environmental measures and other items. |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in orders received in the chemicals and processing businesses and cost improvements in the equipment business are cited as factors behind the increase in profit. The disclosure also explains the impact of higher costs, including raw material prices, labor costs and other expenses, as well as the recognition of provisions for environmental measures.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.